Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JR-171 (lepunafusp alfa) in MPS I
NCT04227600Phase 2Completed
- Sponsor
- JCR Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 2 trial of lepunafusp alfa in mucopolysaccharidosis type I, sponsored by JCR Pharmaceuticals. Started Sep 2020; status: completed.
02
Drugs
lepunafusp alfa
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT04227600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227600.